Funding & Disinvestments

Siemens Healthineers will contribute US$5.4 million in cost sharing, bringing the total potential investment to US$36.5 million.

The acquisition follows Novartis AG’s decision in 2024 to review the future of its India-listed subsidiary.

The investment will upgrade Resilience’s manufacturing operations in Ohio, where the company has produced Lilly’s Mounjaro and Zepbound since the partners began working together in 2023.

Following completion of the transaction, the business will operate under the new name Medswana Laborex and become part of CFAO Healthcare’s pan-African network.

The ambitious project targets approximately 1.2 million residents, most of whom inhabit rural communities where traditional connectivity has remained inconsistent.

I-MED operates a network of 215 clinics across Australia and New Zealand and performs more than seven million patient procedures annually.

Under the collaboration, the companies will evaluate Helicons both as standalone therapies and as payloads linked to Regeneron antibodies.

The approval applies to adolescents and adults weighing at least 35 kilograms who have haemophilia A with factor VIII inhibitors or haemophilia B with factor IX inhibitors.

The platform debuted across the UAE, France, Germany, Portugal, and the UK, with additional international rollouts planned in the coming months.